Viropro, Inc. Appoints Cynthia Ekberg Tsai as Chairperson of its Board of Directors

VIROPRO (VPRO.PK) today announced the appointment of Ms. Cynthia Ekberg Tsai as the Chairperson of its Board of Directors to further support Viropro’s plans and strategy for global growth.

Ms. Tsai will provide Viropro with her expertise in private equity financing and development of high-growth companies by securing private capitalization from high-net worth investors. Ms. Tsai spent 16 years on Wall Street as a Vice President with Merrill Lynch and Kidder Peabody. She has been involved in venture funding, IPOs, and investor relations specifically in the healthcare space. Ms. Tsai is the Founder and CEO of HealthExpo, the largest consumer healthcare event in the US, where she grew the enterprise from concept to execution, attracting more than 50 million consumers to HealthExpo. Previously, Ms. Tsai was a General Partner in MassTech Ventures, a multi-million dollar equity fund focused on technology development at Massachusetts Institute of Technology. Ms. Tsai serves on the Board of Selectors for the Jefferson Awards, is a Member of the Women's Foreign Policy Group, a member of the Asia Society, and an Advisor to Avjet Biotech. In 1999, the Harvard Business School Alumni Chapter in New York recognized Tsai with an Early Stage Honor Roll Award for Entrepreneurship. In 2004, she also received a “Leading Woman Entrepreneur of the World” Award from the Star Foundation in Overland Park, Kansas. She earned a B.A. in Psychology from the University of Missouri.

According to Dr. Rajiv Datar, President and CEO of Viropro, “Recognizing the dynamic growth of the biotech contract research space, which includes contract development and manufacturing activities, Cynthia Tsai is a valuable resource for the current and future development of Viropro. Her financial expertise and healthcare experience and successes will be invaluable in advising, assessing, and accelerating Viropro’s growth.”

Ms. Tsai commented, “Joining Viropro in the capacity of a Chairperson is an honor and a wonderful opportunity to advance the biotech contract research and manufacturing (CRAMS) space as a whole. Work in healthcare, specifically in the biotech CRAMS space, provides a unique opportunity with a noble underpinning in terms of cost, scientific and technological development, and job creation. I am pleased to be joining Viropro on this mission.”

About Viropro, Inc.:

Viropro, Inc. conducts operations through its subsidiaries Viropro International Inc., Biologics Process Development, Inc., Alpha Biologics Ltd. and Alpha Biologics Sdn. Bhd. Viropro’s principal objective is to provide high-yield development and GMP manufacturing services to biopharmaceutical companies in global markets with unmet medical and/or market needs. The Company specializes in the transfer of its core and proprietary technologies for industrial production of biopharmaceutical therapeutic proteins for the treatment of various diseases including cancer, diabetes, hepatitis and multiple sclerosis. (www.viropro.com)

Viropro Inc. Safe Harbor Statement

Except for any historic information contained herein, the matters discussed in this press release contain forward-looking statements that involve risks and uncertainties, which are subject to section 27A of the Securities Act of 1933 and section 21E of the Exchange Act of 1934, and are subject to safe harbor created by these sections. Any statements that express or involve discussions with respect to predictions, beliefs, plans, projections, objectives, goals, assumptions of future events or performances are not statements of historical fact and may be "forward-looking statements". Forward-looking statements in this release may be identified through the use of such words as "expects", "anticipates", "estimates", "believes", or statements indicating certain actions "may", "could", or "might" occur. Actual results, performance or achievements could differ materially from those anticipated in such forward-looking statements, which involve numerous risks and uncertainties, including the Company's ability to market its products and services in a competitive environment as well as other factors.

Viropro (CE) (USOTC:VPRO)
過去株価チャート
から 11 2024 まで 12 2024